Despite showing promising clinical efficacy in some blood cancers [1], PI3K/mTOR inhibitors lack single-agent cytotoxicity in aggressive diseases like DLBCL [45]. This evidence concerns the gene PIK3CD and hematopoietic and lymphoid system neoplasm.